• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含III型纤连蛋白结构域蛋白1基因在泛癌中的预后及免疫意义及其与胃腺癌增殖和迁移的关系

The prognostic and immune significance of fibronectin type III domain-containing 1 gene in pan-cancer and its relationship with proliferation and migration of stomach adenocarcinoma.

作者信息

Deng Minying, Huang Wen, Luo Rongkui, Wang Huimei, Yu Zixiang, Ma Benting, Xu Lei, Zhang Xiaolei, Su Jieakesu, Xu Chen, Hou Yingyong

机构信息

Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.

出版信息

Transl Cancer Res. 2025 May 30;14(5):3069-3095. doi: 10.21037/tcr-2024-2279. Epub 2025 May 20.

DOI:10.21037/tcr-2024-2279
PMID:40530118
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12170108/
Abstract

BACKGROUND

Fibronectin type III domain containing 1 (FNDC1) exhibits emerging roles in tumorigenesis, yet its pan-cancer implications and mechanistic contributions to stomach adenocarcinoma (STAD) remain underexplored. This study systematically evaluates FNDC1's prognostic relevance, immune interactions, and functional impact in STAD.

METHODS

Multi-omics analyses integrated FNDC1 expression, mutation profiles, and immune associations across 33 cancers using The Cancer Genome Atlas (TCGA) data. Immunohistochemistry assessed FNDC1, mismatch repair (MMR) protein, and human epidermal growth factor receptor 2 (HER2), and clinicopathological information was collected for statistical analysis. Finally, we conducted in vitro experiments to assess the effects of FNDC1 knockdown on STAD.

RESULTS

In various cancers, the main genetic alterations of are mutations and deep deletions, with a mutation frequency of 10% observed primarily in malignant melanoma and endometrial carcinoma. The expression levels of messenger RNA (mRNA) in breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), and STAD are significantly higher than those in adjacent normal tissues (P<0.05). In STAD, FNDC1 shows significant correlations with cell infiltrations such as endothelial cells, eosinophils, granulocyte-monocyte progenitors, hematopoietic stem cells, macrophage M1, macrophage M2, monocytes, myeloid dendritic cells, and activated myeloid dendritic cells. In STAD, FNDC1 exhibits significant positive correlations with immune checkpoints HAVCR2 and PDCD1LG2. Proteins with similar expression patterns to FNDC1 and ranking in the top 100 include GNAS, GNB1, MXRA5, COL3A1, COL10A1, ASPN, SFRP2, SFRP4, FXYD2, and GNG2. Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analysis shows that in STAD, -related genes are involved in pathways such as neuroactive ligand-receptor interaction, calcium signaling, cAMP signaling, vascular smooth muscle contraction, and pancreatic secretion. Gene Ontology (GO) functional enrichment analysis in STAD shows that FNDC1-related genes are involved in pathways related to the muscle system process, collagen-containing extracellular matrix, and receptor ligand activity. Clinical sample analysis demonstrates that FNDC1 protein is upregulated in STAD compared to adjacent normal tissues (P<0.05). Age, tumor size, tumor differentiation, Lauren classification, lymphovascular invasion, neural invasion, tumor deposit, postoperative recurrence, T stage, N stage, M stage, tumor-node-metastasis (TNM) stage, HER2 expression, and MMR protein expression are relevant risk factors for poor prognosis in STAD patients, with age, tumor size, Lauren classification, lymphovascular invasion, neural invasion, and postoperative recurrence being independent risk factors affecting prognosis. Vitro experiments demonstrate that knocking down FNDC1 can decrease the proliferation, migration and invasion abilities of STAD.

CONCLUSIONS

FNDC1 is highly expressed in various tumor tissues and may serve as a potential prognostic biomarker and immunotherapy target in cancer. It plays a crucial role in proliferation, migration and invasion of STAD.

摘要

背景

含III型纤连蛋白结构域1(FNDC1)在肿瘤发生中发挥着新出现的作用,但其在泛癌中的意义以及对胃腺癌(STAD)的机制性作用仍未得到充分研究。本研究系统地评估了FNDC1在STAD中的预后相关性、免疫相互作用和功能影响。

方法

利用癌症基因组图谱(TCGA)数据,多组学分析整合了33种癌症中FNDC1的表达、突变谱和免疫关联。免疫组织化学评估了FNDC1、错配修复(MMR)蛋白和人表皮生长因子受体2(HER2),并收集临床病理信息进行统计分析。最后,我们进行了体外实验以评估FNDC1敲低对STAD的影响。

结果

在各种癌症中,主要的基因改变是突变和深度缺失,在恶性黑色素瘤和子宫内膜癌中观察到的突变频率为10%。乳腺浸润性癌(BRCA)、胆管癌(CHOL)、结肠腺癌(COAD)、食管癌(ESCA)、头颈部鳞状细胞癌(HNSC)、肾透明细胞癌(KIRC)和STAD中FNDC1信使核糖核酸(mRNA)的表达水平显著高于相邻正常组织(P<0.05)。在STAD中,FNDC1与内皮细胞、嗜酸性粒细胞、粒细胞-单核细胞祖细胞、造血干细胞、巨噬细胞M1、巨噬细胞M2、单核细胞、髓样树突状细胞和活化的髓样树突状细胞等细胞浸润显著相关。在STAD中,FNDC1与免疫检查点HAVCR2和PDCD1LG2呈显著正相关。与FNDC1表达模式相似且排名前100的蛋白质包括GNAS、GNB1、MXRA5、COL3A1、COL10A1、ASPN、SFRP2、SFRP4、FXYD2和GNG2。京都基因与基因组百科全书(KEGG)功能富集分析表明,在STAD中,与FNDC1相关的基因参与神经活性配体-受体相互作用、钙信号、环磷酸腺苷(cAMP)信号、血管平滑肌收缩和胰腺分泌等途径。STAD中的基因本体论(GO)功能富集分析表明,FNDC1相关基因参与与肌肉系统过程、含胶原蛋白的细胞外基质和受体配体活性相关的途径。临床样本分析表明,与相邻正常组织相比,STAD中FNDC1蛋白上调(P<0.05)。年龄、肿瘤大小、肿瘤分化、劳伦分类、淋巴管侵犯、神经侵犯、肿瘤沉积物、术后复发、T分期、N分期、M分期、肿瘤-淋巴结-转移(TNM)分期、HER2表达和MMR蛋白表达是STAD患者预后不良的相关危险因素,年龄、肿瘤大小、劳伦分类、淋巴管侵犯、神经侵犯和术后复发是影响预后的独立危险因素。体外实验表明,敲低FNDC1可降低STAD的增殖、迁移和侵袭能力。

结论

FNDC1在各种肿瘤组织中高表达,可能作为癌症潜在的预后生物标志物和免疫治疗靶点。它在STAD的增殖、迁移和侵袭中起关键作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/e0de2a7f9174/tcr-14-05-3069-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/98cfdf74be05/tcr-14-05-3069-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/454287a4f132/tcr-14-05-3069-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/af217e6e7d98/tcr-14-05-3069-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/821e95478875/tcr-14-05-3069-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/6aa0b1a579c4/tcr-14-05-3069-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/1f843b8d0349/tcr-14-05-3069-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/9f2cdf7f7351/tcr-14-05-3069-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/e0de2a7f9174/tcr-14-05-3069-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/98cfdf74be05/tcr-14-05-3069-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/454287a4f132/tcr-14-05-3069-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/af217e6e7d98/tcr-14-05-3069-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/821e95478875/tcr-14-05-3069-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/6aa0b1a579c4/tcr-14-05-3069-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/1f843b8d0349/tcr-14-05-3069-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/9f2cdf7f7351/tcr-14-05-3069-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5c/12170108/e0de2a7f9174/tcr-14-05-3069-f8.jpg

相似文献

1
The prognostic and immune significance of fibronectin type III domain-containing 1 gene in pan-cancer and its relationship with proliferation and migration of stomach adenocarcinoma.含III型纤连蛋白结构域蛋白1基因在泛癌中的预后及免疫意义及其与胃腺癌增殖和迁移的关系
Transl Cancer Res. 2025 May 30;14(5):3069-3095. doi: 10.21037/tcr-2024-2279. Epub 2025 May 20.
2
Comprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk factor and its potential prognostic value in SKCM.全面的泛癌分析揭示NTN1作为一种免疫浸润风险因素及其在皮肤黑色素瘤中的潜在预后价值。
Sci Rep. 2025 Jan 25;15(1):3223. doi: 10.1038/s41598-025-85444-x.
3
Integrated pan-cancer analysis of ADM's role in prognosis, immune modulation and resistance.ADM在预后、免疫调节和耐药性方面作用的综合泛癌分析
Front Immunol. 2025 Jun 3;16:1573250. doi: 10.3389/fimmu.2025.1573250. eCollection 2025.
4
Construction and validation of a prognostic model for glioma: an analysis based on mismatch repair-related genes and their correlation with clinicopathological features.胶质瘤预后模型的构建与验证:基于错配修复相关基因及其与临床病理特征相关性的分析
Transl Cancer Res. 2025 May 30;14(5):2690-2706. doi: 10.21037/tcr-24-2045. Epub 2025 May 9.
5
Comprehensive pan-cancer analysis and experimental validation reveal FCHSD1 as a potential biomarker for diagnosis, immune infiltration, and prognosis.全面的泛癌分析和实验验证表明,FCHSD1是一种用于诊断、免疫浸润和预后的潜在生物标志物。
Front Oncol. 2025 Jun 4;15:1547067. doi: 10.3389/fonc.2025.1547067. eCollection 2025.
6
Development and validation of a Log odds of negative lymph nodes/T stage ratio-based prognostic model for gastric cancer.基于阴性淋巴结/肿瘤分期比值的胃癌对数优势预后模型的开发与验证
Front Oncol. 2025 Jun 3;15:1554270. doi: 10.3389/fonc.2025.1554270. eCollection 2025.
7
Dissecting the multi-omics landscape of TEAD1 in hepatocellular carcinoma: cycle regulation and metastatic potential.剖析肝细胞癌中TEAD1的多组学格局:细胞周期调控与转移潜能
Front Immunol. 2025 Jun 5;16:1567969. doi: 10.3389/fimmu.2025.1567969. eCollection 2025.
8
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.基于分子特征的腹膜后脂肪肉瘤分类:一项前瞻性队列研究。
Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887.
9
Identification of DCAF5 as a novel cancer prognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation.通过泛癌分析和肾透明细胞癌临床数据验证,鉴定DCAF5作为一种新型癌症预后和免疫治疗生物标志物。
Discov Oncol. 2025 Jun 16;16(1):1119. doi: 10.1007/s12672-025-02974-6.
10
Prognostic role of tumor microenvironment and immune- and autophagy-related genes in colorectal adenocarcinoma.肿瘤微环境以及免疫和自噬相关基因在结直肠癌中的预后作用
Transl Cancer Res. 2025 May 30;14(5):2835-2857. doi: 10.21037/tcr-24-1708. Epub 2025 May 27.

本文引用的文献

1
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
2
[FNDC1 is highly expressed in lung adenocarcinoma and closely related with poor prognosis].纤连蛋白结构域包含蛋白1(FNDC1)在肺腺癌中高表达,且与不良预后密切相关。
Nan Fang Yi Ke Da Xue Xue Bao. 2022 Aug 20;42(8):1182-1190. doi: 10.12122/j.issn.1673-4254.2022.08.10.
3
Up-regulated FNDC1 accelerates stemness and chemoradiation resistance in colorectal cancer cells.
FNDC1 上调促进结直肠癌细胞干性和放化疗抵抗。
Biochem Biophys Res Commun. 2022 Apr 30;602:84-90. doi: 10.1016/j.bbrc.2022.02.038. Epub 2022 Feb 25.
4
The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway.FNDC1 的沉默通过调节 PI3K/Akt 信号通路抑制乳腺癌细胞的肿瘤发生。
Mol Med Rep. 2021 Jun;23(6). doi: 10.3892/mmr.2021.12118. Epub 2021 Apr 26.
5
Proteomic Architecture of Valvular Extracellular Matrix: FNDC1 and MXRA5 Are New Biomarkers of Aortic Stenosis.瓣膜细胞外基质的蛋白质组学结构:FNDC1和MXRA5是主动脉瓣狭窄的新型生物标志物。
JACC Basic Transl Sci. 2021 Jan 13;6(1):25-39. doi: 10.1016/j.jacbts.2020.11.008. eCollection 2021 Jan.
6
Cancer Statistics, 2021.癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
7
Pan-cancer RNA-seq data stratifies tumours by some hallmarks of cancer.泛癌 RNA-seq 数据通过癌症的一些标志性特征对肿瘤进行分类。
J Cell Mol Med. 2020 Jan;24(1):418-430. doi: 10.1111/jcmm.14746. Epub 2019 Nov 15.
8
The Immune Landscape of Cancer.癌症的免疫格局
Immunity. 2019 Aug 20;51(2):411-412. doi: 10.1016/j.immuni.2019.08.004.
9
Expression Analysis of Fibronectin Type III Domain-Containing (FNDC) Genes in Inflammatory Bowel Disease and Colorectal Cancer.含纤连蛋白III结构域(FNDC)基因在炎症性肠病和结直肠癌中的表达分析
Gastroenterol Res Pract. 2019 Apr 9;2019:3784172. doi: 10.1155/2019/3784172. eCollection 2019.
10
Epidemiology of gastric cancer: global trends, risk factors and prevention.胃癌流行病学:全球趋势、风险因素与预防
Prz Gastroenterol. 2019;14(1):26-38. doi: 10.5114/pg.2018.80001. Epub 2018 Nov 28.